For complete information about the report, please visit our website
https://www.reportscorner.com/reports/14937/MITSUBISHI-TANABE-,-Outperform---Invokana:-Nice-to-Have-A-Clean-Label,-Yet-A-Long-Way-To-Go-Before-Gaining-Full-Confidence!-/
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the 'clean label'.
https://www.reportscorner.com/reports/14937/MITSUBISHI-TANABE-,-Outperform---Invokana:-Nice-to-Have-A-Clean-Label,-Yet-A-Long-Way-To-Go-Before-Gaining-Full-Confidence!-/
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the 'clean label'.
No comments:
Post a Comment